financetom
Business
financetom
/
Business
/
Alkami Technology Insider Sold Shares Worth $3,133,550, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alkami Technology Insider Sold Shares Worth $3,133,550, According to a Recent SEC Filing
Aug 20, 2024 2:11 PM

04:37 PM EDT, 08/20/2024 (MT Newswires) -- W Bryan Hill, Chief Financial Officer, on August 19, 2024, sold 100,000 shares in Alkami Technology ( ALKT ) for $3,133,550. Following the Form 4 filing with the SEC, Hill has control over a total of 489,340 shares of the company, with 489,340 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1529274/000152927424000175/xslF345X03/wk-form4_1724186000.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ZimVie Announces Completion of its Acquisition by ARCHIMED
ZimVie Announces Completion of its Acquisition by ARCHIMED
Oct 20, 2025
PALM BEACH GARDENS, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. ( ZIMV ) (“ZimVie”), a global life sciences leader in the dental implant market, today announced that ARCHIMED, an investment firm focused exclusively on healthcare industries, has completed its previously announced acquisition of ZimVie ( ZIMV ). Pursuant to the terms of the transaction announced on July 20,...
Halozyme Therapeutics' Royalty Growth and Cost Control to Drive Q3 Earnings, Morgan Stanley Says
Halozyme Therapeutics' Royalty Growth and Cost Control to Drive Q3 Earnings, Morgan Stanley Says
Oct 20, 2025
09:00 AM EDT, 10/20/2025 (MT Newswires) -- Halozyme Therapeutics' ( HALO ) strength in royalty revenues and cost discipline will drive Q3 earnings, Morgan Stanley said in a note Monday. Morgan Stanley expects Q3 revenue of $346 million and diluted earnings of $1.47 per share, both slightly above consensus estimates. Halozyme's revenue and earnings should benefit from its Enhanze platform,...
Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says
Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says
Oct 20, 2025
09:00 AM EDT, 10/20/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) is tracking well for a meaningful expansion opportunity for its Ziihera beyond biliary tract cancer into gastroesophageal adenocarcinoma, Morgan Stanley said in a note Sunday. Analysts at Morgan Stanley added that the balance sheet strategy and business development execution is critical to support the terminal value. Jazz is...
Beyond Meat Stock Surges After Debt Swap: No Bankruptcy, But Tons of Dilution
Beyond Meat Stock Surges After Debt Swap: No Bankruptcy, But Tons of Dilution
Oct 20, 2025
After a year of financial strain and fear of insolvency, Beyond Meat, Inc. ( BYND ) surprised the market with a sudden rally on Monday — even as it handed most of the company over to its bondholders.  BYND stock is soaring. See the real-time price action here.  Debt Swap Beyond Meat ( BYND ) stock surged more than 24% after...
Copyright 2023-2026 - www.financetom.com All Rights Reserved